Table 1.
Baseline Characteristics
| Total | Time Period |
||||
|---|---|---|---|---|---|
| 1998-2002 | 2003-2007 | 2008-2012 | 2013-2017 | ||
| Demographics | |||||
| n | 619 | 58 | 144 | 183 | 234 |
| Male | 63.0 | 62.1 | 59.0 | 62.3 | 66.2 |
| Age at first cardiac manifestation, y | 68.2 (59.9-75.8) | 66.3 (53.8-74.6) | 65.7 (57.2-74.4) | 67.4 (59.7-75.9) | 70.4 (63.2-76.6) |
| Age at amyloidosis diagnosis, y | 69.9 (61.5-77.1) | 67.4 (53.9-75.1) | 66.0 (58.0-76.8) | 68.9 (61.2-76.3) | 71.6 (64.7-79.0) |
| Age at baseline, y | 70.0 (63.0-77.8) | 67.4 (53.9-75.2) | 66.9 (59.4-77.1) | 70.5 (61.4-76.7) | 72.3 (66.0-79.3) |
| Cardiac manifestation or amyloidosis first diagnosed? | |||||
| Cardiac manifestationa | 62.0 | 65.5 | 56.3 | 60.7 | 65.8 |
| Time between first cardiac manifestation and subsequently diagnosed amyloidosis, yb | 1.26 (0.20-4.70) | 0.63 (0.20-2.17) | 1.95 (0.24-5.04) | 0.92 (0.12-4.78) | 1.39 (0.24-5.03) |
| Comorbidities | |||||
| Ischemic heart disease | 24.9 | 22.4 | 25.0 | 27.9 | 23.1 |
| Acute myocardial infarction | 7.6 | 5.2 | 7.6 | 11.5 | 5.1 |
| Heart failure | 29.9 | 29.3 | 25.7 | 28.4 | 33.8 |
| Atrial fibrillation | 29.7 | 25.9 | 25.7 | 30.6 | 32.5 |
| Hypertension | 28.1 | 17.2 | 25 | 29 | 32.1 |
| Diabetes | 14.1 | 10.3 | 13.2 | 13.1 | 16.2 |
| Stroke | 7.3 | 6.9 | 3.5 | 9.3 | 8.1 |
| Chronic obstructive pulmonary disease | 9.4 | 6.9 | 6.9 | 9.3 | 11.5 |
| Chronic renal failure | 27.0 | 17.2 | 27.1 | 31.2 | 26.1 |
| MGUSc | 5.8 | 3.5 | 6.3 | 3.8 | 7.7 |
| Multiple myeloma | 17.3 | 15.5 | 16.0 | 17.5 | 18.4 |
| Treatment with melphalan ± concomitant corticosteroids, bortezomib, thalidomide, or daratumumab or received stem cell conditioning | 15.4 | 0 | 4.9 | 17.5 | 23.9 |
| Suspected amyloid light chain amyloidosisd | 23.4 | 15.5 | 18.8 | 26.8 | 25.6 |
| Education | |||||
| Masters/doctoral degree or equivalent tertiary education level (ISCED 7-8) | 3.1 | 1.7 | 2.8 | 3.8 | 3 |
| Income | |||||
| Highest quartile incomee | – | 24.1 | 27.1 | 25.7 | 23.1 |
| Inpatient vs outpatient diagnosis of amyloidosis | |||||
| Inpatient | 55.1 | 67.2 | 69.4 | 49.2 | 47.9 |
| Outpatient | 43.1 | 25.9 | 27.8 | 49.7 | 51.7 |
Values are n, median (interquartile range), or %, unless otherwise noted.
ISCED = International Standard Classification of Education.
a
Cardiac manifestation = heart failure, cardiomyopathy, atrial fibrillation, or pacemaker implantation.
b
Calculated only for those in whom cardiac manifestation was first.
c
Monoclonal gammopathy of unknown significance. Present at baseline, even if >10 years previous.
d
Defined as multiple myeloma and/or treatment with melphalan ± concomitant corticosteroids, bortezomib, thalidomide, or daratumumab or received stem cell conditioning.
e
Calculated using mean household income during the 5-year period before baseline.